The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...

Leerink Partners analyst Mike Kratky has maintained their neutral stance on INSP stock, giving a Hold rating on December 9.Don't Miss Our ...

Coming off of Novo Nordisk's (NVO) sharp stock decline after its experimental weight-loss shot CagriSema was found to help recipients lose less weight than previously forecasted, BMO Capital Markets ...

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

In a groundbreaking move, the US Food and Drug Administration (FDA) has approved the anti-diabetic drug Zepbound, also known ...

The United States Food and Drug Administration (FDA) has approved the weight-loss drug Tirzepatide — sold by the brand name ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 502.93% and ...

The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to cheaper versions could end.

The US FDA has approved the anti-diabetic drug Zepbound (Tirzepatide) for managing obstructive sleep apnea (OSA) in obese ...

The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...